Thermo Fisher Scientific’s shares dropped over 1% following reports of exploring a sale of part of its diagnostics unit, including its microbiology business, with a potential valuation of around $4 billion. The diagnostics segment, comprising clinical and transplant diagnostics among others, generated $4.51 billion in revenues last year but faces challenges post-COVID with tariff impacts and macroeconomic uncertainties. The company’s strategic move reflects ongoing sector consolidation and adaptation to changing funding environments, though no final decisions have been disclosed. Industry observers watch for further shifts as the diagnostics market grapples with growth and investment limitations.